Cover Image
市場調查報告書

前列腺癌:日本的醫藥品的預測與市場分析

Prostate Cancer - Japan Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 262450
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
Back to Top
前列腺癌:日本的醫藥品的預測與市場分析 Prostate Cancer - Japan Drug Forecast and Market Analysis to 2023
出版日期: 2015年04月08日 內容資訊: 英文 187 Pages
簡介

本報告提供日本的前列腺癌市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊,主要藥物的銷售額預測,主要活動的影響分析,推動市場要素、阻礙因素等驗證。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理學
  • 階段
  • 症狀
  • 預後
  • 生活品質(QOL)

第4章 疾病管理

  • 診斷治療概要
  • 美國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌 - 標靶治療
  • 產品簡介:領導品牌 - 化療
  • 產品簡介:領導品牌 - 治療疫苗
  • 產品簡介:領導品牌 - 荷爾蒙療法
  • 產品簡介:領導品牌 - 骨病變治療

第6章 機會及未滿足需求

第7章 開發平台評估

  • 概要
  • 產品簡介:免疫療法
  • 產品簡介:標靶治療

第8章 市場預測

  • 美國

第9章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC343CFR

Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. . Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon's Provenge, Sanofi's Jevtana, Johnson & Johnson's Zytiga, Medivation/Astellas' Xtandi, and Bayer's Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.

The Japanese market for prostate cancer will grow significantly over the forecast period. As none of the branded prostate cancer therapies for CRPC were available in Japan in 2013, GlobalData expects there will be rapid uptake of Xtandi, Jevtana and Zytiga, which all launched in Japan in 2014.

Scope

  • Overview of Prostate Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Prostate Cancer market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate Cancer.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Staging
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Screening and Diagnosis
    • 4.1.2. Treatment Guidelines and the Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands, Targeted Therapies
    • 5.2.1. Zytiga (abiraterone acetate)
    • 5.2.2. Xtandi (enzalutamide)
    • 5.2.3. Xofigo (radium 223 dichloride)
  • 5.3. Product Profiles - Major Brands, Chemotherapies
    • 5.3.1. Jevtana (cabazitaxel)
  • 5.4. Product Profiles - Major Brands, Therapeutic Vaccines
    • 5.4.1. Provenge (sipuleucel-T)
  • 5.5. Product Profiles - Major Brands, Hormone Therapies
    • 5.5.1. Zoladex (goserelin acetate)
    • 5.5.2. Lupron Depot (leuprolide acetate)
    • 5.5.3. Eligard (leuprolide acetate)
    • 5.5.4. Trelstar (triptorelin acetate)
    • 5.5.5. Firmagon (degarelix)
    • 5.5.6. Casodex (bicalutamide)
  • 5.6. Product Profiles - Major Brands, Bone Therapies
    • 5.6.1. Zometa (zoledronic acid)
    • 5.6.2. Xgeva (denosumab)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapeutic Options for nmCRPC Patients
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Identification of Biomarkers to Predict Zytiga and Xtandi Resistance
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Defining the Best Sequence of Drugs to Manage mCRPC
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Product Profiles - Immunotherapies
    • 7.2.1. Yervoy (ipilimumab)
    • 7.2.2. ProstVac
    • 7.2.3. ProstAtak
    • 7.2.4. DCVAC/PCa
    • 7.2.5. ITK1
  • 7.3. Product Profiles - Targeted Therapies
    • 7.3.1. Custirsen Sodium
    • 7.3.2. Tasquinimod
    • 7.3.3. ARN-509
    • 7.3.4. ODM-201

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Prostate Cancer Patients
    • 9.4.2. Percentage Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Director of Oncology
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: TNM Classification of Prostate Cancer
  • Table 2: Prostate Cancer Staging
  • Table 3: Risk-Group Classifications Used in Prostate Cancer
  • Table 4: Most Commonly Used Treatment Guidelines for Prostate Cancer, 2014
  • Table 5: Most Commonly Prescribed Hormonal Therapies for Prostate Cancer, 2014
  • Table 6: Most Commonly Prescribed Chemotherapeutic, Drug, and Bone Therapies for CRPC, 2014
  • Table 7: Diagnosis and Treatment of Prostate Cancer Country Profile - Japan
  • Table 8: Leading Branded Drugs Used to Treat Prostate Cancer, 2014
  • Table 9: Product Profile - Zytiga
  • Table 10: Zytiga SWOT Analysis, 2014
  • Table 11: Global Sales Forecasts ($m) for Zytiga, 2013-2023
  • Table 12: Product Profile - Xtandi
  • Table 13: Xtandi SWOT Analysis, 2014
  • Table 14: Global Sales Forecasts ($m) for Xtandi, 2013-2023
  • Table 15: Product Profile - Xofigo
  • Table 16: Xofigo SWOT Analysis, 2014
  • Table 17: Global Sales Forecasts ($m) for Xofigo, 2013-2023
  • Table 18: Product Profile - Jevtana
  • Table 19: Jevtana SWOT Analysis, 2014
  • Table 20: Global Sales Forecasts ($m) for Jevtana, 2013-2023
  • Table 21: Product Profile - Provenge
  • Table 22: Provenge SWOT Analysis, 2014
  • Table 23: Global Sales Forecasts ($m) for Provenge, 2013-2023
  • Table 24: Product Profile - Zoladex
  • Table 25: Zoladex SWOT Analysis, 2014
  • Table 26: Product Profile - Lupron
  • Table 27: Lupron SWOT Analysis, 2014
  • Table 28: Product Profile - Eligard
  • Table 29: Eligard SWOT Analysis, 2014
  • Table 30: Product Profile - Trelstar
  • Table 31: Trelstar SWOT Analysis, 2014
  • Table 32: Product Profile - Firmagon
  • Table 33: Firmagon SWOT Analysis, 2014
  • Table 34: Product Profile - Casodex
  • Table 35: Casodex SWOT Analysis, 2014
  • Table 36: Product Profile - Zometa
  • Table 37: Zometa SWOT Analysis, 2014
  • Table 38: Product Profile - Xgeva
  • Table 39: Xgeva SWOT Analysis, 2014
  • Table 40: Unmet Need and Opportunity in Prostate Cancer
  • Table 41: Drugs in Phase III Clinical Trials for Prostate Cancer
  • Table 42: Product Profile - Yervoy
  • Table 43: Yervoy SWOT Analysis, 2014
  • Table 44: Global Sales Forecasts ($m) for Yervoy, 2013-2023
  • Table 45: Product Profile - ProstVac
  • Table 46: ProstVac SWOT Analysis, 2014
  • Table 47: Global Sales Forecasts ($m) for ProstVac, 2013-2023
  • Table 48: Product Profile - ProstAtak
  • Table 49: ProstAtak SWOT Analysis, 2014
  • Table 50: Global Sales Forecasts ($m) for ProstAtak, 2013-2023
  • Table 51: Product Profile - DCVAC/PCa
  • Table 52: DCVAC/PCa SWOT Analysis, 2014
  • Table 53: Global Sales Forecasts ($m) for DCVAC, 2013-2023
  • Table 54: Product Profile - ITK1
  • Table 55: ITK1 SWOT Analysis, 2014
  • Table 56: Global Sales Forecasts ($m) for ITK1, 2013-2023
  • Table 57: Product Profile - Custirsen Sodium
  • Table 58: Custirsen Sodium SWOT Analysis, 2014
  • Table 59: Global Sales Forecasts ($m) for Custirsen Sodium, 2013-2023
  • Table 60: Product Profile - Tasquinimod
  • Table 61: Tasquinimod SWOT Analysis, 2014
  • Table 62: Global Sales Forecasts ($m) for Tasquinimod, 2013-2023
  • Table 63: Product Profile - ARN-509
  • Table 64: ARN-509 SWOT Analysis, 2014
  • Table 65: Global Sales Forecasts ($m) for ARN-509, 2013-2023
  • Table 66: Product Profile - ODM-201
  • Table 67: ODM-201 SWOT Analysis, 2014
  • Table 68: Global Sales Forecasts ($m) for ODM-201, 2013-2023
  • Table 69: Sales Forecasts ($m) for Prostate Cancer in Japan, 2013-2023
  • Table 70: Key Events Impacting Sales for Prostate Cancer in Japan, 2013-2023
  • Table 71: Japan Prostate Cancer Market - Drivers and Barriers, 2013-2023
  • Table 72: Key Launch Dates, Marketed and Pipeline Prostate Cancer Drugs
  • Table 73: Key Patent Expiration or Loss of Market Exclusivity Dates, Marketed Prostate Cancer Drugs
  • Table 74: Average Body Weight and Surface Area Across the 9MM
  • Table 75: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Disease Management Flowchart for Prostate Cancer
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2013-2023
  • Figure 3: Yervoy's Clinical Development
  • Figure 4: Potential Clinical and Commercial Positioning of Yervoy
  • Figure 5: ProstVac's Clinical Development
  • Figure 6: Potential Clinical and Commercial Positioning of ProstVac
  • Figure 7: ProstAtak's Clinical Development
  • Figure 8: Potential Clinical and Commercial Positioning of ProstAtak
  • Figure 9: DCVAC/PCa's Clinical Development
  • Figure 10: Potential Clinical and Commercial Positioning of DCVAC/PCa
  • Figure 11: ITK1's Clinical Development
  • Figure 12: Potential Clinical and Commercial Positioning of ITK1
  • Figure 13: Custirsen Sodium's Clinical Development
  • Figure 14: Potential Clinical and Commercial Positioning of Custirsen Sodium
  • Figure 15: Tasquinimod's Clinical Development
  • Figure 16: Potential Clinical and Commercial Positioning of Tasquinimod
  • Figure 17: ARN-509's Clinical Development
  • Figure 18: Potential Clinical and Commercial Positioning of ARN-509
  • Figure 19: ODM-201's Clinical Development
  • Figure 20: Potential Clinical and Commercial Positioning of ODM-201
  • Figure 21: Sales for Prostate Cancer in Japan by Drug Class, 2023
Back to Top